2 enrolling by invitation. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Enrolling by invitation 2 |
| Phase 2 | 1 | Enrolling by invitation 1 |
Follow Nervous System Neoplasms: new trials by email Literature Review of Nervous System Neoplasms trials Research Report on Nervous System Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis Zilucoplan - Generalized Myasthenia Gravis | Phase 3 | Enrolling by invitation | UCB Biopharma SRL | 8 | 2024-11-19 | 2026-10-02 |
| Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis Efgartigimod IV or Efgartigimod PH20 SC - Generalized Myasthenia Gravis, gMG | Phase 2 / Phase 3 | Enrolling by invitation | argenx | 12 | 2022-08-18 | 2026-11-03 |
Autoimmune Diseases (2) · Autoimmune Diseases of the Nervous System (2) · Immune System Diseases (2) · Neoplasms (2) · Neoplasms by Site (2) · Nervous System Diseases (2) · Neurodegenerative Diseases (2) · Neuromuscular Diseases (2) · Neuromuscular Junction Diseases (2) · Paraneoplastic Syndromes (2) · Paraneoplastic Syndromes, Nervous System (2)
zilucoplan (1)
UCB Biopharma SRL (1) · argenx (1)
Poland (2) · United Kingdom (2) · Belgium (1) · Canada (1) · France (1) · Germany (1) · Israel (1) · Italy (1) · Netherlands (1) · South Korea (1) · Spain (1) · United States (1)
2023 (1)